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INTRODUCTION
New-onset diabetes mellitus is a common metabolic com-
plication following liver transplantation, and it is associated
with poor outcomes in regard to a graft function and a patient
survival (1). It has been reported that the post-transplanta-
tion diabetes mellitus (PTDM) can be reversed within weeks
or months in a considerable number of patients (1, 2). Im-
munosuppressive agents such as calcineurin inhibitors and
corticosteroids are largely responsible for the development
of PTDM (3). Although the reversibility of PTDM is asso-
ciated with the doses of immunosuppressive agents, it is not
sufficiently enough to explain the reversibility of PTDM (4).
In addition, a significant ethnicity-based difference has been
observed in the development of PTDM (5). In this study, we
examined the prevalence of PTDM and the predictive factors
associated with its reversibility following liver transplanta-
tion in Koreans. 
MATERIALS AND METHODS
Subjects and data collection
We reviewed the medical records of 328 patients who un-
derwent liver transplantation from January 2004 to May 2007
at Seoul National University Hospital (SNUH); they were
followed up for more than 6 months. Among these 328 pa-
tients, 97 had diabetes before transplantation and were ex-
cluded from the analysis. 
The capillary plasma glucose levels were measured four
times a day for the first week after transplantation and the
venous plasma glucose levels were measured at least once a
week during hospitalization. After discharge, the venous plas-
ma glucose levels were measured at least once a month for the
first 6 months after transplantation. PTDM was defined as
either requirement of insulin/antidiabetic drugs or a fasting
plasma glucose level of ≥7.0 mM/L on 2 consecutive occa-
sions. Based on these criteria, 34 out of 231 (14.7%) patients
were diagnosed with PTDM.
In addition, we enrolled 40 additional PTDM patients
who underwent liver transplantation in China during the
same period; they were followed up at SNUH for more than
6 months. The absence of diabetes mellitus prior to liver trans-
plantation was confirmed by preoperative fasting plasma glu-
cose levels (n=13) or patients’ past medical history (n=27).
The clinical characteristics of the 2 groups were similar (data
not shown) and, therefore, they were analyzed as one group.
Thus, a total 74 PTDM patients (52 men and 22 women)
were analyzed in this study. Demographic data, clinical char-
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Post-transplantation Diabetes Mellitus Following Liver Transplantation
Post-transplantation diabetes mellitus (PTDM) is reversible in a considerable num-
ber of patients. We examined the prevalence and predictive factors of transient
PTDM following liver transplantation. Forty-two of 74 PTDM patients showed the
clinical features of transient PTDM. Compared with the persistent PTDM patients,
they were characterized by younger age at the time of transplantation (49±7 vs.
53±8 yr, P<0.05), longer time before the development of PTDM (44±59 vs. 13
±20 days, P<0.05), lower rate of hepatitis c virus seropositivity (0.0 vs. 9.4%, P<
0.05), and use of mycophenolate mofetil (59.5 vs. 28.1%, P<0.05). Among these
risk factors, age at the time of transplantation is the single independent predictive
factor associated with the reversibility of PTDM.
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Accepted : 23 August 2008acteristics, and data on drug therapy were obtained from me-
dical records. The mean age of the subjects was 51±8 yr.
Twenty-eight patients received liver allografts from living
donors and 46 patients received liver allografts from cadaver
donors. The primary causes of liver failure were hepatitis B
virus (HBV)-related liver cirrhosis or hepatocellular carcino-
ma (n=67, 90.5%), hepatitis C virus (HCV)-related liver cir-
rhosis or hepatocellular carcinoma (n=3, 4.1%), alcoholic
liver cirrhosis (n=2, 2.7%), fulminant hepatitis (n=1, 1.4%),
and liver cirrhosis of unknown etiology (n=1, 1.4%). All the
patients were administered tacrolimus plus steroid-based
immunosuppressive therapy. Mycophenolate mofetil (MMF)
was administered to 34 of 74 patients (45.9%). The preop-
erative clinical characteristics between patients who received
or did not receive MMF treatment were similar (data not
shown). 
The PTDM patients were classified into 2 groups, name-
ly, transient PTDM and persistent PTDM. Transient PTDM
was defined as recovery from PTDM with the maintenance
of fasting plasma glucose level at <5.6 mM/L and HbA1c
at <6.0% without insulin or any antidiabetic medication for
more than 6 months. Otherwise, they were classified into the
persistent PTDM group. In transient PTDM group, 47.6%
were diagnosed by requirement of insulin/antidiabetic drugs
and 52.4% by high fasting plasma glucose levels; in persis-
tent PTDM group, 56.3% were diagnosed by requirement
of insulin/antidiabetic drugs and 43.7% by high fasting plas-
ma glucose levels. 
Statistical analysis
All continuous variables were expressed as mean±SD. Stu-
dent’s t test or Mann-Whitney U test was used to compare
the continuous variables between the 2 groups. Pearson’s chi-
square test or Fischer’s exact test was used for comparing cat-
egorical variables. Binary logistic regression analysis was used
for determining the multiple predictive factors associated with
transient PTDM. A P value <0.05 was considered statisti-
cally significant. All the analyses were performed using SPSS
for Windows (SPSS, Chicago, IL, U.S.A.).
RESULTS
Among the 74 PTDM patients, 42 (56.8%) showed tran-
sient PTDM, while 32 (43.2%) showed persistent PTDM.
In the transient PTDM group, the mean duration from diag-
nosis to recovery of PTDM was 6.6±6.6 months. Table 1
showed the clinical characteristics between the transient and
persistent PTDM patients. Compared to the patients with
persistent PTDM, those with transient PTDM were charac-
terized by younger age at the time of transplantation (49±
7 vs. 53±8 yr, P<0.05), longer time before the development
of PTDM (44±59 vs. 13±20 days, P<0.05), a lower rate
of HCV seropositivity (0.0 vs. 9.4%, P<0.05), and more fre-
quent use of MMF (59.5 vs. 28.1%, P<0.05). In contrast, no
significant differences were detected with regard to the body
mass index (BMI) and fasting plasma glucose levels at the
time of liver transplantation, and family history of diabetes.
The cumulative dose of prednisolone during the previous 30
days of each time point did not show any difference between
the 2 groups, and the plasma tacrolimus trough levels also
did not show any difference. For initial treatment to control
hyperglycemia, all the patients with persistent PTDM were
treated by insulin and the patients with transient PTDM were
treated by insulin (n=37, 88.1%), oral antidiabetic drugs (n=
3, 7.1%), or life style modification alone (n=2, 4.3%). 
Based on a multivariate analysis (Table 2), age at the time
of transplantation was determined as the single independent
predictive factor associated with reversibility of new-onset
diabetes mellitus following liver transplantation (odds ratio,
1.252 [95% confidence interval, 1.004-1.562]). 
DISCUSSION
We hereby demonstrated that new-onset diabetes follow-
ing liver transplantation was transient in 56.8% of the pati-
ents and the mean time period from the onset of PTDM to
recovery was 6.6±6.6 months. Age at the time of transplan-
tation was the single independent predictive factor associat-
ed with the reversibility of PTDM in a multivariate analysis.
It was reported that age at the time of renal allograft trans-
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Data are expressed as mean±SD or percentage.
*Body mass index at the time of liver transplantation.
HCV, hepatitis C virus; PTDM, post-transplantation diabetes mellitus.
Transient
group
Persistent
group
P
Number 42 32
Sex (M/F)  28/14 24/8 0.398
Age at transplantation (yr) 49±75 3 ±8 <0.05
Body mass index (kg/m
2)* 23.3±2.8 23.0±3.7 0.710
Family history of diabetes (%) 13.2 10.0 0.688
Time for PTDM development (days) 44±59 13±20 <0.05
HCV infection (%) 0 9.4 <0.05
Pretransplantation fasting plasma 5.4±0.9 5.1±0.7 0.269
glucose (mM/L)
Cumulative prednisolone dose 
(mg/previous 30 days)
1 month after transplantation 497.7±23.8 474.3±18.6 0.483
3 months after transplantation 310.9±80.0 299.2±62.5 0.662
6 months after transplantation 68.3±80.9 79.2±63.7 0.686
Tacrolimus trough level (ng/mL)
1 month after transplantation 9.6±3.6 9.0±4.3 0.549
3 months after transplantation 8.7±2.7 8.3±2.9 0.628
6 months after transplantation 8.7±3.1 8.0±3.4 0.435
Use of mycophenolate mofetil (%) 59.5 28.1 <0.05
Table 1. Comparison of clinical characteristicsplantation (particularly ≥40 yr) was the predictive factor
for the occurrence of future PTDM in Koreans (6). In addi-
tion, an age of ≥40 yr denoted a higher risk of persistent
PTDM in Korean renal allograft recipients (7). Consistent
with these findings in renal allograft transplantation patients,
the current study showed that age at the time of transplan-
tation was the single independent predictive factor associat-
ed with the reversibility of PTDM in liver allograft recipi-
ents. Interestingly, all patients with persistent PTDM were
≥40 yr of age at the time of transplantation (data not shown). 
In the current study, 9.4% of persistent PTDM patients
but none of the transient PTDM patients had HCV infec-
tion. HCV infection was not only associated with the devel-
opment of PTDM but also associated with persistent PTDM
(2, 8). It was recently shown that HCV infection was inde-
pendently associated with increased insulin resistance in liver
transplantation patients (9). In addition, HCV could direct-
ly infect human pancreatic beta cells, which might eventu-
ally lead to beta-cell dysfunction (10). For the generalization
of the association between HCV infection and PTDM, a fur-
ther study with sufficient number of patients would be nec-
essary.
The time period from liver transplantation to PTDM devel-
opment was shown to be significantly different between tran-
sient and persistent PTDM patients. It was expected that the
earlier PTDM developed, the higher was the risk of persis-
tent PTDM. This finding suggests that liver allograft recip-
ients susceptible to the development of PTDM are also at a
greater risk of developing persistent PTDM. 
Reduction in the dose of tacrolimus and steroids was report-
ed to be related to the reversibility of PTDM (4). In this study,
we found that more frequent use of MMF was associated with
transient PTDM, and that the mean trough level of tacrolimus
was lower in the patients receiving MMF (8.3±2.5 vs. 9.7
±2.8 ng/mL, P<0.05). Thus, dose-saving effect of MMF on
tacrolimus might be partly responsible for the reversibility
of PTDM. 
There are several limitations in this study. First, the absence
of oral glucose tolerance test might raise the possibility of
ascertainment bias. Second, the retrospective study design
cannot firmly conclude the data regarding the predictive fac-
tors. Third, the possible heterogeneity caused by including
the patients who underwent liver transplantation in China
could be the weak point of this study, even though there was
no significant difference in their clinical characteristics com-
pared to those of the patients who received the liver allograft
at SNUH.
In conclusion, 56.8% of the patients with new-onset dia-
betes following liver transplantation showed transient PTDM
and the age at the time of transplantation was the single inde-
pendent predictive factor associated with the reversibility.
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